CMO of Denali
Carole Ho is our Chief Medical Officer and serves as Head of Development. Carole most recently served as Vice President of Genentech Early Clinical Development. In that role, she was responsible for delivery of pivotal trial-ready drug candidates to the Roche / Genentech late-stage development groups in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8 year tenure at Genentech, Carole held positions of increasing responsibility across both the early and late stage clinical development groups with development oversight for multiple therapeutic areas and molecules including crenezumab for Alzheimer’s Disease, ocrelizumab for Multiple Sclerosis, Lampalizumab for dry AMD, and the sBLA approval of Rituxan for Wegener’s granulomatosis and microscopic polyangiitis. Carole received her undergraduate degree in Biochemical Sciences from Harvard College and her M.D. from Cornell University. Carole completed her Medical Internship and Neurology residency at Harvard and served as Chief Resident of Neurology at the Massachusetts General Hospital / Brigham and Women’s Hospital. Prior to Genentech, Carole was on Faculty in the Department of Neurology at Stanford University and subsequently a Medical Director at Johnson and Johnson.